Pathology Service - Home About Us Staff Divisions Clinical Services Education and Training Research Intranet
 
Pathology Service Staff
MGH Pathology Service | Last updated:  September 21, 2009


Advancing Diagnosis and Discovery

David N. Louis, MD

Pathologist-in-Chief
Benjamin Castleman Professor of Pathology
Massachusetts General Hospital
Warren 225
Boston, MA 02114

Phone: 617-726-2966
Fax: 617-726-7533

Email: dlouis@partners.org

Affiliations:
MGH Cancer Center
MGH Neurosurgery

Signout: Neuropathology surgicals and autopsies.

Research Interests:

Our laboratory investigates the molecular genetic basis of human brain tumors.

Brain tumors are the second most frequent malignancy of childhood and are common in adults, affecting nearly 20,000 people each year in the United States. Brain tumors are also among the most devastating of human malignancies, affecting the organ that defines the "self" and thus severely compromising quality of life. Malignant gliomas of the cerebral hemispheres in adults are the most common of brain tumors and are the focus of our laboratory efforts.

Elucidating the molecular basis of glioma formation may impact both diagnostic and therapeutic aspects of clinical neuro-oncology. We have demonstrated alterations characteristic of specific glioma subtypes and grades. We originally demonstrated that molecular genetic analysis could be used to define clinicopathologically relevant subsets of glioblastomas. We have also shown that molecular genetic alterations (most notably losses of chromosome arms 1p and 19q) are powerful predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. Hence, genotyping can direct therapeutic choices for these patients, and is now used in clinical practice. The group also showed that class prediction models, based on defined expression profiles, classify diagnostically challenging malignant gliomas in a manner that better correlates with clinical outcome than does standard pathology. The laboratory has also discovered a mechanism underlying therapeutic resistance in recurrent glioblastomas, and is studying the mechanistic basis of chemoresistance in glioblastoma.

To achieve its translational research goals, the laboratory applies a wide variety of molecular pathology approaches—such as expression profiling, laser capture microdissection, tissue microarrays, quantitative RT-PCR out of paraffin-embedded materials, and array comparative genomic hybridization on DNA obtained from paraffin embedded material—to study malignant gliomas. The laboratory is also involved in molecular genetic study of other forms of primary human brain tumors. In particular, we have studied the genetic basis of certain inherited neurological tumor syndromes, such as neurofibromatosis 2. We have also functioned as a reference laboratory for standard and molecular pathological analyses, including for the Dana-Farber/Harvard Cancer Center, for the brain tumor group of the NCI's Mouse Models of Human Cancer Consortium, and for ongoing studies of gene therapy in glioblastomas.

__________________________________________________________

Bibliography of David N. Louis via Pubmed (will open in new window)

Members of the Laboratory

David Louis
Gayatry Mohapatra
James Kim
RK Narayanan
Michael Jansen
Sandra Camelo-Piragua
Mai Nitta
Stephen Yip

   
 
 
Send us a comment or suggestion
Page Updated: September 21, 2009
Privacy and Terms of Use